Outpatient Community-Acquired Pneumonia: Who Goes Home, Which Antibiotic and Follow-Up

Outpatient community-acquired pneumonia (CAP) turns on three decisions: whether the patient is safe at home, which empiric antibiotic fits the patient's comorbidity profile, and how to follow up. Under the ATS/IDSA 2019 guideline, an adult with a low severity score, adequate oxygenation and reliable support goes home. Healthy adults receive amoxicillin, doxycycline, or a macrolide only where resistance is low, while adults with comorbidities receive a beta-lactam plus a macrolide or doxycycline, or a respiratory fluoroquinolone alone. A 2025 ATS update, which IDSA did not endorse, shortens durations for patients who stabilize quickly.

Assessment: making the diagnosis

CAP is an acute infection of the lung parenchyma acquired outside the hospital. The typical outpatient presents with cough, fever, pleuritic chest pain, dyspnea or sputum, and focal findings such as crackles, bronchial breath sounds or dullness. Older adults may present only with confusion, falls, tachypnea or decline in function, and fever may be absent.

Clinical findings alone do not confirm CAP. A chest radiograph showing a new infiltrate is the standard. The 2025 ATS update accepts lung ultrasound as an alternative when radiography or CT is not readily available and the clinician is trained in point-of-care ultrasound.

Outpatient testing is deliberately limited. ATS/IDSA 2019 recommends against routine sputum Gram stain and culture, blood cultures, and pneumococcal or Legionella urinary antigen testing in outpatients. Test for influenza (and SARS-CoV-2) when those viruses are circulating, because a positive result changes management. Pulse oximetry is essential; a basic metabolic panel and complete blood count help when the severity decision is close.

Who goes home: severity scores with cut-offs

ATS/IDSA 2019 recommends a validated prognostic rule, preferably the Pneumonia Severity Index (PSI) over CURB-65, in addition to clinical judgment. Neither score replaces judgment: hypoxemia, inability to take oral medication, unstable comorbidities, cognitive impairment or lack of home support can justify admission at any score.

The 2007 IDSA/ATS severe CAP criteria, retained in 2019, identify patients who need ICU-level care: either major criterion (septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation) or three or more minor criteria, such as respiratory rate 30 or higher, PaO2/FiO2 ratio 250 or lower, multilobar infiltrates, confusion, BUN 20 mg/dL or higher, leukopenia, thrombocytopenia, hypothermia, or hypotension needing aggressive fluids. Any of these in a clinic patient means emergency transfer.

Which antibiotic: ATS/IDSA 2019 outpatient regimens

The first branch is comorbidity. ATS/IDSA 2019 defines comorbidities as chronic heart, lung, liver or renal disease; diabetes mellitus; alcohol use disorder; malignancy; or asplenia.

Points that shape the choice:

• Macrolide resistance in Streptococcus pneumoniae exceeds 25 percent in much of the United States, so azithromycin monotherapy is rarely the best exam answer.
• Doxycycline as the partner drug in combination therapy carries a weaker evidence grade than a macrolide but is acceptable, especially when QT prolongation is a concern.
• Recent antibiotic exposure (within about 90 days) argues for a drug from a different class.
• Fluoroquinolones carry boxed warnings (tendinopathy and rupture, peripheral neuropathy, CNS effects, dysglycemia, aortic aneurysm risk) and increase Clostridioides difficile risk; reserve them for patients who cannot take the beta-lactam combination.
• Prior respiratory isolation of MRSA or Pseudomonas aeruginosa, or recent hospitalization with parenteral antibiotics, takes the patient out of the standard outpatient algorithm; obtain cultures and usually treat in a supervised setting.
• Anaerobic coverage for suspected aspiration is not added routinely unless lung abscess or empyema is suspected.

Influenza and CAP

A patient with CAP and a positive influenza test receives an influenza antiviral (oseltamivir) regardless of symptom duration. ATS/IDSA 2019 also recommended standard antibacterial treatment for all adults with CAP who test positive for influenza. The 2025 ATS update is narrower: it conditionally recommends empiric antibiotics for outpatients with comorbidities and for all inpatients, and IDSA declined to endorse that update partly over this question. Confirm in the current guideline which approach an item expects.

Duration and the definition of clinical stability

ATS/IDSA 2019 recommends treatment until the patient reaches clinical stability, for no less than 5 days. The 2025 ATS update conditionally recommends a shorter course of 3 to 5 days for outpatients with comorbidities and for non-severe inpatients who achieve stability, while keeping at least 5 days for severe CAP and longer courses for complications or organisms that need them.

Systemic corticosteroids are not used for non-severe CAP. The 2025 ATS update strongly recommends against them in non-severe inpatients and conditionally supports them only in severe CAP (not influenza), which is an inpatient decision.

Monitoring and follow-up intervals

• Contact or review at 48 to 72 hours. Most patients on appropriate therapy show improvement in fever and heart rate within that window.
• Failure to improve at 72 hours, or worsening at any point, prompts reassessment: wrong organism (resistant pneumococcus, atypical, viral, tuberculosis, fungal), a complication (parapneumonic effusion, empyema, abscess), a non-infectious mimic (heart failure, pulmonary embolism, malignancy, organizing pneumonia), or poor adherence. Repeat imaging and referral are appropriate here.
• A visit after completion of therapy to confirm resolution of symptoms, review comorbidities and update vaccines.
• No routine follow-up chest radiograph if symptoms resolve within 5 to 7 days. Patients who qualify for lung cancer screening are screened under the usual rules.

Fatigue and cough often persist for weeks after the infection has cleared, which is expected and not treatment failure.

Referral or admission triggers in the clinic

• PSI class III or higher, CURB-65 of 2 or more, or any severe CAP criterion.
• Hypoxemia on room air or a new oxygen requirement.
• Inability to take or absorb oral medication, vomiting, or dehydration.
• New confusion, hypotension, or tachypnea at 30 or more.
• Pleural effusion, cavitation or multilobar involvement on imaging.
• Immunocompromise, prior MRSA or Pseudomonas isolation, or failure of outpatient therapy.
• Unreliable home support or inability to return for follow-up.

Patient and caregiver education

• Take the full prescribed course and the antiviral if influenza is positive.
• Expected course: fever settles within about three days; cough and fatigue may last weeks.
• Return or call for worsening breathlessness, chest pain, confusion, persistent fever beyond 72 hours, lips turning blue, or inability to keep fluids down. Caregivers of older adults should watch for new confusion or reduced intake.
• Rest, hydration and acetaminophen for fever; avoid smoking.
• Fluoroquinolone counseling when prescribed: stop and call for tendon pain, palpitations or numbness.
• Vaccines after recovery: pneumococcal, influenza, COVID-19 and RSV according to the current CDC adult schedule.

How the exam tests this

• Azithromycin alone for everyone. It is correct only for a healthy adult in an area with macrolide resistance under 25 percent; most items expect amoxicillin or doxycycline.
• Missing the comorbidity. A patient with diabetes, COPD, heart failure, chronic kidney disease, alcohol use disorder or asplenia needs combination therapy or a fluoroquinolone, not amoxicillin alone.
• Fluoroquinolone for a healthy 30-year-old. It works but is not first line and carries avoidable harm.
• Ordering sputum and blood cultures in a clinic patient. The guideline recommends against routine testing in outpatients.
• Admitting by gut feel. Items supply the CURB-65 components; add them up. Equally, a low score does not override hypoxemia.
• A routine follow-up chest x-ray at six weeks for a patient who has fully recovered is a distractor.
• Adding steroids "to speed recovery" in non-severe CAP is wrong.

Practice question

A 58-year-old man presents with three days of productive cough, fever of 38.6 C and right-sided pleuritic chest pain. He has type 2 diabetes managed with metformin and no other conditions. He took no antibiotics in the past year and has no history of resistant organisms. He is alert. Respiratory rate is 22, blood pressure 132/80 mm Hg, heart rate 98, and SpO2 95 percent on room air. BUN is 14 mg/dL. Chest radiograph shows a right lower lobe infiltrate. Influenza testing is negative. He lives with his wife. Which of the following is the most appropriate management?

• A. Azithromycin 500 mg on day 1, then 250 mg daily for four days.
• B. Amoxicillin-clavulanate 875/125 mg twice daily plus azithromycin, with reassessment in 48 to 72 hours.
• C. Admit for intravenous ceftriaxone and azithromycin.
• D. Obtain sputum culture and blood cultures before starting amoxicillin 1 g three times daily.

Answer: B. His CURB-65 score is 0 (alert, BUN under 20, respiratory rate under 30, normal blood pressure, under 65), so outpatient care is appropriate, but diabetes is a comorbidity under ATS/IDSA 2019, which calls for a beta-lactam such as amoxicillin-clavulanate plus a macrolide or doxycycline, or a respiratory fluoroquinolone alone. Option A is macrolide monotherapy, which the guideline limits to patients without comorbidities and only where resistance is under 25 percent. Option C admits a low-risk patient who meets every criterion for home treatment. Option D orders cultures the guideline recommends against in outpatients and uses amoxicillin alone, which is the regimen for a patient without comorbidities.

Key points

Related NPPace guides

• Sore Throat in the Clinic: Centor Scoring, When to Test for Strep and What to Prescribe
• UTI Antibiotic Choices and Durations: Cystitis, Pyelonephritis, Men, Pregnancy and Recurrence
• Asthma Step Therapy on the NP Exam: GINA Tracks, Stepping Up and Stepping Down
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?